Go Pro
NASDAQ:ACB

Aurora Cannabis (ACB) Stock Price, News & Analysis

Aurora Cannabis logo
$3.66 -0.03 (-0.68%)
As of 10:16 AM Eastern
This is a fair market value price provided by Massive. Learn more.

About Aurora Cannabis Stock (NASDAQ:ACB)

Advanced

Key Stats

Today's Range
$3.62
$3.67
50-Day Range
$2.58
$3.82
52-Week Range
$2.56
$6.66
Volume
120,714 shs
Average Volume
1.13 million shs
Market Capitalization
$236.99 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
Moderate Buy

Company Overview

Aurora Cannabis Inc. (NASDAQ: ACB) is a Canadian licensed producer of medical and consumer cannabis products headquartered in Edmonton, Alberta. Established in 2013, the company operates under Health Canada’s regulations to cultivate, process and distribute a range of cannabis-based offerings. Since its initial public listing in 2017, Aurora has grown into one of the country’s largest growers by cultivation capacity and production output.

The company’s core business spans the cultivation of dried flower, the extraction of cannabis oils and the development of value-added products such as softgels, capsules and topical treatments. Aurora serves both the medical market—with products distributed through physicians and pharmacies—and the adult‐use market in jurisdictions where recreational cannabis is legal. Its portfolio includes proprietary genetics and branded offerings designed to deliver consistent cannabinoid and terpene profiles.

Aurora operates several state-of-the-art production facilities, including high-tech greenhouses and indoor cultivation sites, most notably the Aurora Sky campus near Edmonton. The company holds EU Good Manufacturing Practice (GMP) certification, enabling exports to key European markets such as Germany, Italy and Denmark, and maintains partnerships in Latin America, Australia and parts of the Asia Pacific region. Through strategic investments and acquisition of international distribution platforms, Aurora seeks to extend its reach into emerging cannabis markets.

Leadership at Aurora Cannabis has evolved since its founding, with Chairman and Chief Executive Officer Miguel Martin overseeing a shift toward operational efficiency and product innovation. The company’s early leadership team included co-founders Terry Booth and Steve Dobler, who guided initial expansion and public-market entry. Aurora has also pursued notable acquisitions—such as MedReleaf in 2018—to bolster production capacity and diversify its product mix. Looking ahead, Aurora aims to leverage its research capabilities and global infrastructure to capture growth opportunities in both medical and adult-use cannabis sectors.

AI Generated. May Contain Errors.

Aurora Cannabis Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
29th Percentile Overall Score

ACB MarketRank™: 

Aurora Cannabis scored higher than 29% of companies evaluated by MarketBeat, and ranked 789th out of 915 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Aurora Cannabis has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 strong buy rating, 1 buy rating, 1 hold rating, and 1 sell rating.

  • Amount of Analyst Coverage

    Aurora Cannabis has only been the subject of 3 research reports in the past 90 days.

  • Read more about Aurora Cannabis' stock forecast and price target.
  • Earnings Growth

    Earnings for Aurora Cannabis are expected to grow in the coming year, from ($0.07) to $0.06 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Aurora Cannabis is -2.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Aurora Cannabis is -2.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Aurora Cannabis has a P/B Ratio of 0.59. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Aurora Cannabis' valuation and earnings.
  • Percentage of Shares Shorted

    12.77% of the float of Aurora Cannabis has been sold short.
  • Short Interest Ratio / Days to Cover

    Aurora Cannabis has a short interest ratio ("days to cover") of 6.73.
  • Change versus previous month

    Short interest in Aurora Cannabis has recently decreased by 1.07%, indicating that investor sentiment is improving.
  • Dividend Yield

    Aurora Cannabis does not currently pay a dividend.

  • Dividend Growth

    Aurora Cannabis does not have a long track record of dividend growth.

  • News Sentiment

    Aurora Cannabis has a news sentiment score of 0.49. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.68 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 19 news articles for Aurora Cannabis this week, compared to 4 articles on an average week.
  • Search Interest

    Only 3 people have searched for ACB on MarketBeat in the last 30 days. This is a decrease of -73% compared to the previous 30 days.
  • MarketBeat Follows

    14 people have added Aurora Cannabis to their MarketBeat watchlist in the last 30 days. This is an increase of 1,300% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Aurora Cannabis insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    0.01% of the stock of Aurora Cannabis is held by insiders.

  • Percentage Held by Institutions

    47.63% of the stock of Aurora Cannabis is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Aurora Cannabis' insider trading history.
Receive ACB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aurora Cannabis and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ACB Stock News Headlines

Ticker Revealed: Pre-IPO Access to "Next Elon Musk" Company
We’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billion in government contracts. Peter Thiel just bet $1 Billion on it.tc pixel
Curaleaf logo displayed with cannabis leaves and a bud on a reflective surface against a dark green background.
Joint Operations: Curaleaf Makes a Play for Aurora Cannabis
Curaleaf's unsolicited $272 million tender offer for Aurora Cannabis targets EU-GMP cultivation capacity, with Aurora's board forming a special committee to evaluate the cash-and-stock bid.
Curaleaf launches hostile bid for Aurora Cannabis
See More Headlines

ACB Stock Analysis - Frequently Asked Questions

Aurora Cannabis' stock was trading at $4.22 at the beginning of the year. Since then, ACB shares have decreased by 12.8% and is now trading at $3.68.

Aurora Cannabis Inc. (NASDAQ:ACB) issued its earnings results on Wednesday, August, 5th. The company reported $0.04 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.13) by $0.17. The firm had revenue of $47.62 million for the quarter, compared to analysts' expectations of $47.45 million. Aurora Cannabis had a negative net margin of 32.26% and a positive trailing twelve-month return on equity of 4.37%.
Read the conference call transcript
.

Shares of Aurora Cannabis reverse split before market open on Tuesday, February 20th 2024.The 1-10 reverse split was announced on Tuesday, February 20th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, February 20th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

The following companies are subsidiaries of Aurora Cannabis: Reliva LLC, Whistler Medical Marijuana Corporation, ICC Labs Inc., Anandia Labs Inc, MedReleaf Corp., CanniMed Therapeutics Inc., Larssen Ltd, and others.

Top institutional investors of Aurora Cannabis include State of Wyoming (0.03%).

Shares of ACB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Aurora Cannabis investors own include Canopy Growth (CGC), Cronos Group (CRON), NVIDIA (NVDA), Meta Platforms (META), Humana (HUM), American Water Works (AWK).

Company Calendar

Last Earnings
8/05/2026
Today
8/17/2026
Next Earnings (Estimated)
11/04/2026
Fiscal Year End
3/31/2027

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:ACB
Previous Symbol
NYSE:ACB
CIK
1683541
Fax
N/A
Employees
1,028
Year Founded
2006

Profitability

EPS (Trailing Twelve Months)
($1.41)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$88.13 million
Net Margins
-32.26%
Pretax Margin
-11.84%
Return on Equity
4.37%
Return on Assets
3.45%

Debt

Debt-to-Equity Ratio
0.03
Current Ratio
5.36
Quick Ratio
2.80

Sales & Book Value

Annual Sales
$247.82 million
Price / Sales
0.95
Cash Flow
$0.69 per share
Price / Cash Flow
5.24
Book Value
$6.27 per share
Price / Book
0.58

Miscellaneous

Outstanding Shares
64,840,000
Free Float
64,836,000
Market Cap
$236.02 million
Optionable
Optionable
Beta
0.58

Social Links

(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

This page (NASDAQ:ACB) was last updated on 8/17/2026 by MarketBeat.com Staff.
From Our Partners